How to Fight Insurance Denials for Psoriasis and Psoriatic Arthritis Treatment

If you have moderate-to-severe plaque psoriasis or psoriatic arthritis (PsA), your dermatologist or rheumatologist may prescribe a biologic—drugs like Humira, Cosentyx, Skyrizi, or Taltz—or newer oral medications like Sotyktu or Rinvoq. These therapies can be life-changing, but insurers routinely deny them, citing "not medically necessary" or demanding you fail cheaper drugs first, even when those treatments have already failed or aren't appropriate for your disease. Denials are common because these drugs cost $60,000–$90,000 per year, and insurers use rigid step-therapy protocols that ignore the nuances of psoriatic disease: nail involvement that threatens your livelihood, genital psoriasis that destroys intimacy, erosive arthritis that requires aggressive early treatment, or prior biologic failure that makes IL-23 or IL-17 inhibitors the right next step. This guide explains how to fight back with the clinical evidence and policy language insurers actually respect.

Why Insurers Deny Psoriasis and PsA Treatment

1. "Step therapy not completed"

The insurer requires you to fail topical steroids, phototherapy, methotrexate, or Otezla before approving a biologic—even if you've already tried and failed those treatments, or they're contraindicated (e.g., methotrexate in someone planning pregnancy, phototherapy unavailable in your rural area, or topicals futile for 20% body surface area involvement).

2. "Not moderate-to-severe disease"

The denial claims your psoriasis is "mild" based on limited documentation in the prior authorization. Insurers often use arbitrary thresholds (e.g., body surface area <10%) and ignore quality-of-life impact or special-site involvement (scalp, face, genitals, nails, palms/soles) that makes "limited" disease functionally disabling.

3. "Requested drug not preferred; try formulary alternative first"

Your doctor prescribed Skyrizi, but the plan demands you try Humira or Enbrel first—even if you've already failed a TNF inhibitor or have comorbid Crohn's disease (where IL-17 inhibitors like Cosentyx can worsen gut inflammation). This is step therapy disguised as formulary control.

4. "Insufficient trial of conventional therapy"

The insurer claims you haven't tried methotrexate, sulfasalazine, or leflunomide for "adequate duration" (often demanding 3–6 months), even when you had dose-limiting toxicity (elevated liver enzymes, nausea, cytopenias) or contraindications (active hepatitis, alcohol use disorder, pregnancy planning).

5. "Psoriatic arthritis not documented"

For PsA indications, the denial states "no objective evidence of inflammatory arthritis"—ignoring your rheumatologist's exam findings of tender/swollen joints, dactylitis (sausage digits), enthesitis (tendon insertion inflammation), elevated inflammatory markers, or imaging showing erosions or sacroiliitis.

The Citations Insurers Respect

When you appeal, reference these specific guidelines and trials by name. Insurers design their medical policies around them, and citing them forces the reviewer to reconcile the denial with the plan's own coverage criteria.

Clinical guidelines

• AAD-NPF Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis (2019, updated 2020): Defines moderate-to-severe psoriasis as BSA ≥10%, PASI ≥12, or involvement of special sites (face, genitals, hands, feet, nails) regardless of BSA. Recommends biologics or oral systemics when topicals/phototherapy fail.
• ACR/NPF Guideline for the Treatment of Psoriatic Arthritis (2018): Recommends TNF inhibitors, IL-17 inhibitors, or IL-12/23 inhibitors as first-line for active PsA; JAK inhibitors and IL-23 inhibitors for TNF-inadequate responders.
• GRAPPA Treatment Recommendations (2021, updated 2023): Group for Research and Assessment of Psoriasis and Psoriatic Arthritis consensus on domain-based treatment (skin, peripheral arthritis, axial disease, enthesitis, dactylitis).

Landmark trials (cite these for specific drugs)

• ERASURE/FIXTURE trials (NEJM 2014): Cosentyx (secukinumab) Phase III trials showing PASI 75 in 82% at week 12 vs 5% placebo.
• UNCOVER-1/2/3 trials (NEJM 2016): Taltz (ixekizumab) showing PASI 90 in 71% vs 3% placebo; superior nail clearance.
• BE VIVID/BE READY trials (Lancet 2021, NEJM 2023): Bimzelx (bimekizumab) dual IL-17A+F inhibition, PASI 100 in 59% week 16.
• UltIMMa-1/2 trials (NEJM 2018): Skyrizi (risankizumab) IL-23p19 inhibitor, PASI 90 in 75% week 16, durable to 52 weeks.
• VOYAGE 1/2 trials (NEJM 2017): Tremfya (guselkumab) PASI 90 in 73% week 16.
• PHOENIX 1/2 trials (Lancet 2008): Stelara (ustekinumab) IL-12/23 inhibitor, established efficacy across weight bands.
• POETYK PSO-1/2 trials (NEJM 2021): Sotyktu (deucravacitinib) oral TYK2 inhibitor, PASI 75 in 58% vs 13% placebo, oral alternative to injectables.
• DISCOVER-1/2 trials (Lancet 2020, Arthritis Rheumatol 2021): Tremfya in PsA, ACR20 64% week 24 (TNF-naïve), effective in enthesitis/dactylitis.
• SPIRIT-P1/P2 trials (Lancet 2018): Taltz in PsA, simultaneous skin and joint improvement, effective in TNF-IR population.
• SELECT-PsA 1 trial (NEJM 2021): Rinvoq (upadacitinib) JAK1 inhibitor in PsA, ACR20 71% week 12.

FDA label dates (use to counter "investigational" claims)

• Cosentyx: FDA-approved January 2015 (plaque psoriasis), January 2016 (PsA).
• Taltz: March 2016 (plaque), December 2017 (PsA).
• Bimzelx: October 2023 (plaque), September 2024 (PsA/axSpA/AS).
• Skyrizi: April 2019 (plaque), January 2022 (PsA).
• Tremfya: July 2017 (plaque), July 2020 (PsA).
• Ilumya: March 2018 (plaque only).
• Sotyktu: September 2022 (plaque).
• Rinvoq: December 2021 (PsA indication).
• Vtama: May 2022 (plaque adults), December 2024 (ages 2+).
• Zoryve: July 2022 (plaque cream), December 2023 (foam scalp/body).

How to Argue Against "Step Therapy Not Completed"

Concrete steps

1. Document prior conventional therapy failures comprehensively. In your appeal letter, create a table:

- Topical clobetasol 0.05% twice daily × 12 weeks (2024): Partial scalp improvement, no trunk/limb control, skin atrophy on elbow plaques.

- NB-UVB phototherapy 3×/week × 10 weeks (2024): PASI improvement 55%, relapsed 3 weeks after stopping, clinic 45-minute drive each way (unsustainable).

- Methotrexate 20 mg SC weekly × 5 months (2025): ALT rose to 89 (>2× ULN), held for hepatotoxicity; PASI improvement only 40% at peak.

- Otezla 30 mg BID × 4 months (2025): PASI 35% improvement, discontinued for intractable nausea and 12-pound weight loss.

2. Invoke the AAD-NPF 2019 guideline: "The American Academy of Dermatology and National Psoriasis Foundation 2019 Guidelines of Care state that biologic therapy is appropriate first-line for moderate-to-severe psoriasis when conventional therapies are ineffective, contraindicated, or poorly tolerated. This patient meets all three criteria."

3. Cite your state's step-therapy override law (if applicable). States including California, Connecticut, Illinois, Louisiana, Maryland, New York, and others have laws requiring insurers to grant exceptions when:

- The required step drug is contraindicated or likely to cause an adverse reaction.

- The required step drug is expected to be ineffective based on known clinical characteristics.

- The patient has tried and failed the step drug (or another in the same class) previously.

- The patient is stable on the requested drug (coverage continuity).

4. For methotrexate specifically: If they demand MTX and you can't take it, attach documentation: abnormal liver function tests, the prescribing information contraindication for hepatic disease, your gastroenterologist's note contraindicating it due to NASH/cirrhosis, or the rheumatologist's note documenting severe nausea/vomiting at 15 mg weekly (before reaching therapeutic 20–25 mg).

5. For pregnancy planning: If you're planning pregnancy, cite the FDA Pregnancy Category for methotrexate (X—contraindicated) and note that Cimzia (certolizumab) has no Fc region, doesn't cross the placenta appreciably, and has the best pregnancy safety data among biologics. The ACR 2020 guideline on reproductive health states TNF inhibitors compatible with pregnancy can be continued; demanding MTX first is unsafe.

How to Argue Against "Not Moderate-to-Severe Disease"

Concrete steps

1. Quantify your disease with validated scales:

- BSA (body surface area): Use the handprint rule (your palm = 1% BSA). If you have confluent plaques on both shins, both forearms, scalp, and lower back, that's easily 15–20% BSA. Take photographs with a ruler for scale and date-stamp them.

- PASI (Psoriasis Area and Severity Index): Your physician calculates this (0–72 scale); PASI ≥12 = severe. Request the score be documented in every note.

- DLQI (Dermatology Life Quality Index): Self-administered 10-question survey. DLQI >10 = "very large effect on quality of life." Fill it out and attach it to your appeal.

2. Highlight special-site involvement. The AAD-NPF guideline explicitly states that psoriasis of the face, scalp, genitals, palms, soles, or nails is considered moderate-to-severe regardless of BSA due to functional and psychosocial impact. In your letter:

- "The 2019 AAD-NPF guideline designates genital psoriasis as moderate-to-severe regardless of body surface area due to profound impact on sexual function and quality of life. My involvement of the glans penis and inguinal folds has caused relationship breakdown and severe psychological distress (DLQI 18)."

- "Nail psoriasis (NAPSI score 42, with pitting, onycholysis, and oil-drop changes across 8 fingernails) interferes with my work as a dental hygienist and is explicitly designated moderate-to-severe in the AAD-NPF 2019 guideline, warranting systemic therapy."

3. Use quality-of-life evidence. Attach your completed DLQI, a letter from a therapist documenting depression/anxiety secondary to psoriasis, days-of-work-missed documentation, or photos showing plaques on hands (if you work in hospitality/healthcare and patients recoil from your hands).

4. Challenge arbitrary thresholds. If the denial says "BSA <10% does not meet criteria," write: "Cigna's own medical policy #0262 (Psoriasis Treatment, updated 2025) cites the AAD-NPF 2019 guideline, which defines moderate-to-severe disease as BSA ≥3% if involving high-impact areas such as hands, feet, face, or genitals. This patient has 6% BSA with 80% scalp involvement and palmar psoriasis affecting occupational function."

How to Argue Against "Try Formulary Alternative First"

Concrete steps

1. Document prior failure of the insurer's preferred drug. If they want you to try Humira but you already failed it, attach:

- Progress notes documenting inadequate response after 16 weeks (the standard efficacy timeframe): "PASI improved only 28% on adalimumab 40 mg every 2 weeks × 16 weeks, meeting criteria for primary non-response per GRAPPA 2021 treatment recommendations."

- Drug levels if available (low adalimumab level + high anti-drug antibodies = immunogenicity-mediated failure, unlikely to respond to another TNF inhibitor).

2. Argue for class switching based on mechanism. If you failed a TNF inhibitor, cite the ACR/NPF 2018 guideline and GRAPPA 2021 consensus: after TNF-inhibitor failure, switching to a different mechanism (IL-17, IL-23, JAK) is preferred over trying a second TNF inhibitor.

- "The SPIRIT-P2 trial (Lancet 2018) demonstrated that ixekizumab (Taltz) achieved ACR20 in 53% of TNF-inadequate responders, establishing IL-17 inhibition as evidence-based after TNF failure. Requiring a second TNF inhibitor contradicts ACR/NPF 2018 guideline recommendations."

3. Invoke comorbidity-based contraindications:

- Crohn's or ulcerative colitis: "This patient has biopsy-proven Crohn's disease. IL-17 inhibitors (Cosentyx/Taltz/Bimzelx) are relatively contraindicated due to reports of new-onset or exacerbated IBD (FDA warnings 2017–2023). The requested IL-23 inhibitor (Skyrizi) or TNF inhibitor (Humira) is IBD-safe; the formulary alternative (Cosentyx) is not."

- Congestive heart failure (CHF): "TNF inhibitors are contraindicated in NYHA Class III/IV heart failure per FDA black-box warnings and the 2019 AAD-NPF guideline. This patient has EF 30% (cardiologist letter attached). The requested IL-23 inhibitor (Tremfya) has no cardiac contraindication."

- Demyelinating disease or family history: "Patient's sister has multiple sclerosis; TNF inhibitors carry FDA warnings for demyelination risk. The requested IL-17 inhibitor is mechanistically unrelated and appropriate."

4. Cite your plan's own medical policy. Many insurers' policies state "alternative agent preferred if contraindication or previous adverse reaction to formulary agent exists." Request a copy of the policy (cite the policy number from your denial letter) under your right to an internal appeal, then quote it back.

How to Argue Against "Insufficient Trial of Conventional Therapy"

Concrete steps

1. Define "adequate trial" per the literature. Cite the ACR/NPF 2018 guideline: an adequate trial of methotrexate is ≥3 months at ≥15 mg/week (or maximal tolerated dose if lower). If you took MTX 15 mg weekly × 4 months and had <20% improvement, that's an adequate failed trial.

2. Document why you couldn't reach therapeutic dose:

- ALT/AST elevation (attach lab reports): "Methotrexate was escalated to 20 mg weekly; ALT rose to 92 U/L (ref <33). Per prescribing information and AAD-NPF 2019 guideline, dose held due to hepatotoxicity. Further escalation contraindicated."

- GI intolerance: "Severe nausea and vomiting on methotrexate 15 mg weekly despite ondansetron and leucovorin rescue; unable to tolerate escalation to therapeutic 20–25 mg dose."

- Cytopenias: "WBC dropped to 2.8 × 10⁹/L on methotrexate 20 mg weekly; drug held per hematology consultation."

3. Invoke contraindications. Attach documentation:

- Pregnancy planning: OB-GYN letter stating "Patient desires conception within 6 months; methotrexate is FDA Pregnancy Category X and must be discontinued ≥3 months pre-conception. Biologics with favorable pregnancy data (certolizumab) are appropriate."

- Alcohol use disorder: Psychiatry note documenting AUD; methotrexate contraindicated due to hepatotoxicity risk.

- Chronic kidney disease: Nephrology note showing GFR 38 mL/min; methotrexate dose-reduction required, unlikely to reach therapeutic levels.

4. For phototherapy unavailability: If they demand NB-UVB and you lack access, attach:

- Letter from your dermatologist: "Patient resides in rural Montana, 180 miles from nearest phototherapy center. Three-times-weekly treatment for 12 weeks (36 visits × 6-hour round-trip) is not feasible. Home phototherapy unit cost $4,000 out-of-pocket, not covered by insurance. Biologic therapy is the only practical systemic option."

How to Argue Against "PsA Not Documented"

Concrete steps

1. Provide objective exam findings. Insurers want numbers. Your rheumatologist's appeal letter should include:

- Tender joint count (TJC) and swollen joint count (SJC): "Physical exam: TJC 12, SJC 8, involving bilateral PIPs, DIPs, wrists, and left knee."

- Dactylitis: "Sausage digit left 3rd toe and right 4th finger, Leeds Dactylitis Index 28."

- Enthesitis: "Tenderness bilateral Achilles insertions and left plantar fascia insertion, Leeds Enthesitis Index 3, SPARCC Enthesitis Index 6."

- Axial features (if spondylitis): "Inflammatory back pain: morning stiffness 90 minutes, improves with activity. BASDAI 6.8. Schober test 3 cm (limited lumbar flexion)."

2. Attach inflammatory markers: CRP ≥5 mg/L or ESR ≥20 mm/hr supports active inflammation. Even if normal, note "~40% of PsA patients are seronegative and have normal acute-phase reactants per ACR/NPF 2018 guideline."

3. Include imaging reports:

- X-rays: "Hand X-ray: erosive changes DIPs 2nd and 3rd digits bilaterally, pencil-in-cup deformity right 4th DIP. Radiographic damage confirms erosive PsA per ACR/NPF 2018."

- MRI: "Sacroiliac joint MRI: bone marrow edema bilateral SI joints, meeting ASAS criteria for active sacroiliitis, consistent with axial PsA."

- Ultrasound: "Power Doppler ultrasound: synovial hypertrophy and hyperemia right wrist and left 2nd MCP, grade 2/3."

4. Cite the CASPAR criteria. The Classification Criteria for Psoriatic Arthritis (CASPAR) require inflammatory articular disease (joint, spine, or entheseal) plus ≥3 points from: current psoriasis (2 points), personal history of psoriasis (1 point), family history of psoriasis (1 point), dactylitis (1 point), nail changes (1 point), negative rheumatoid factor (1 point), radiographic evidence of juxta-articular new bone formation (1 point). Walk through your patient's score in the appeal: "This patient meets CASPAR criteria with 5 points: current plaque psoriasis (2), dactylitis (1), nail pitting (1), RF-negative (1). Diagnosis of PsA is well-established."

5. Emphasize the need for early aggressive treatment. Cite: "20–40% of PsA patients develop erosive joint damage within 2 years of disease onset (ACR/NPF 2018 guideline). This patient already has radiographic erosions [attach X-ray report]. Delayed access to biologic therapy risks irreversible disability."

What We Do

We are patient advocates who specialize in insurance appeals for dermatology and rheumatology denials. We draft the peer-to-peer rebuttal, organize your clinical records into the format insurers require, cite the guidelines and trials by name, and work with your physician to submit Level 1 (internal) and Level 2 (external) appeals, plus state insurance commissioner complaints when warranted. We handle Aetna, UnitedHealthcare, Cigna, Blue Cross Blue Shield, Humana, Anthem, Kaiser, and regional plans. If you've been denied Skyrizi, Cosentyx, Taltz, Tremfya, Bimzelx, Stelara, Sotyktu, Rinvoq, or any other psoriasis/PsA therapy and need help appealing, we're here.

---

Sources

1. American Academy of Dermatology and National Psoriasis Foundation. Guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.

2. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32.

3. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479.

4. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials (ERASURE and FIXTURE). N Engl J Med. 2014;371(4):326-338.

5. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis (UNCOVER-1, UNCOVER-2, UNCOVER-3). N Engl J Med. 2016;375(4):345-356.

6. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus secukinumab in plaque psoriasis (BE VIVID). N Engl J Med. 2021;385(2):142-152.

7. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.

8. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis (VOYAGE 1 and VOYAGE 2). J Am Acad Dermatol. 2017;76(3):405-417.

9. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39.

10. McInnes IB, Chakravarty SD, Apaolaza I, et al. Efficacy of upadacitinib in patients with psoriatic arthritis by prior biologic use and number: a post hoc analysis of two phase 3 randomized controlled trials (SELECT-PsA 1 and SELECT-PsA 2). RMD Open. 2022;8(2):e002619.

11. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial (SPIRIT-H2H). Ann Rheum Dis. 2020;79(1):123-131.

12. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1 and DISCOVER-2): results from phase 3, randomised, double-blind, placebo-controlled trials. Lancet. 2020;395(10230):1126-1136.

13. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study (CASPAR). Arthritis Rheum. 2006;54(8):2665-2673.

14. U.S. Food and Drug Administration. Prescribing information and approval history for secukinumab (Cosentyx), ixekizumab (Taltz), bimekizumab (Bimzelx), risankizumab (Skyrizi), guselkumab (Tremfya), ustekinumab (Stelara), deucravacitinib (Sotyktu), upadacitinib (Rinvoq). Accessed via Drugs@FDA, 2024–2026.

15. National Psoriasis Foundation. About Psoriatic Disease [patient resources and clinical summaries]. https://www.psoriasis.org. Accessed April 2026.